Wintest
6721
D. Western Therapeutics Institute
4576
Ridge-i
5572
Forside
2330
River Eletec
6666
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -7.98%256.33B | -0.05%1.03T | -12.57%228.42B | -8.02%253.34B | 6.83%268.4B | 15.43%278.56B | 35.11%1.03T | 27.64%261.26B | 41.40%275.44B | 36.34%251.24B |
Cost of revenue | -7.10%224.77B | -0.47%899.1B | -11.97%200.15B | -7.48%222.96B | 5.88%234.04B | 13.09%241.96B | 34.61%903.36B | 26.99%227.37B | 40.94%240.98B | 35.39%221.05B |
Gross profit | -13.79%31.56B | 2.95%129.62B | -16.59%28.27B | -11.83%30.39B | 13.80%34.36B | 33.78%36.6B | 38.79%125.9B | 32.24%33.89B | 44.68%34.46B | 43.69%30.2B |
Operating expense | 22.31%19.51B | 2.53%65.88B | -9.64%15.84B | 6.93%17.08B | 8.66%17.02B | 5.67%15.95B | 18.97%64.26B | 22.69%17.53B | 15.03%15.97B | 21.53%15.66B |
Operating profit | -41.66%12.05B | 3.38%63.73B | -24.03%12.42B | -28.02%13.31B | 19.34%17.35B | 68.38%20.65B | 67.94%61.65B | 44.29%16.35B | 86.08%18.49B | 78.79%14.54B |
Net non-operating interest income (expenses) | 60.69%-252M | 12.11%-1.55B | 76.96%-144M | 37.85%-335M | -4.41%-426M | -242.78%-641M | -556.34%-1.76B | -722.37%-625M | -742.19%-539M | -547.62%-408M |
Non-operating interest income | 255.00%142M | 143.97%344M | 182.76%164M | 30.00%39M | 172.97%101M | 150.00%40M | 116.92%141M | 93.33%58M | 130.77%30M | 208.33%37M |
Non-operating interest expense | -42.14%394M | -0.53%1.89B | -54.90%308M | -34.27%374M | 18.43%527M | 235.47%681M | 470.57%1.9B | 544.34%683M | 638.96%569M | 493.33%445M |
Net investment income | 147.80%87M | 115.42%231M | -59.81%381M | 72.70%-95M | 109.01%127M | 73.55%-182M | -680.21%-1.5B | 358.31%948M | -564.00%-348M | -623.08%-1.41B |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 97.92%-2M | -120.67%-264M | -3,056.00%-789M | -9.66%131M | -37.50%490M | -125.74%-96M | 544.95%1.28B | -25M | 150.70%145M | 9,700.00%784M |
Income from associates and other participating interests | -100.00%-4M | 240.96%351M | 213.33%323M | -13.64%19M | 0.00%11M | -166.67%-2M | 69.18%-249M | -2,135.71%-285M | 102.89%22M | 136.67%11M |
Special income (charges) | -91.67%-69M | 11,589.74%4.56B | 52,957.14%3.7B | 9,040.00%894M | 111.11%1M | -155.38%-36M | -97.93%39M | 41.67%-7M | 37.50%-10M | -101.57%-9M |
Less:Restructuring and mergern&acquisition | ---- | ---3.7B | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
Less:Other special charges | 91.67%69M | -2,094.87%-856M | -57.14%3M | -9,040.00%-894M | -111.11%-1M | 155.38%36M | -205.41%-39M | -41.67%7M | -37.50%10M | -50.00%9M |
Other non-operating income (expenses) | 131.80%69M | 38.66%-803M | 148.97%191M | -53.27%-774M | 99.00%-3M | -92.04%-217M | -2,827.08%-1.31B | -1,795.65%-390M | -1,783.33%-505M | -2,408.33%-301M |
Income before tax | -39.05%11.87B | 13.95%66.26B | 0.71%16.09B | -23.78%13.15B | 32.89%17.55B | 66.23%19.48B | 56.82%58.15B | 46.35%15.97B | 93.54%17.26B | 57.00%13.2B |
Income tax | -40.78%3.4B | 14.31%17.53B | -26.89%2.94B | -17.12%3.7B | 47.26%5.16B | 71.19%5.74B | 60.50%15.34B | 63.10%4.03B | 78.53%4.46B | 51.23%3.5B |
Net income | -38.32%8.48B | 13.83%48.73B | 10.03%13.14B | -26.11%9.46B | 27.69%12.39B | 64.26%13.74B | 55.54%42.81B | 41.44%11.94B | 99.38%12.8B | 59.22%9.7B |
Net income continuous operations | -38.32%8.48B | 13.83%48.73B | 10.02%13.14B | -26.11%9.46B | 27.70%12.39B | 64.24%13.74B | 55.54%42.81B | 41.45%11.94B | 99.38%12.8B | 59.20%9.7B |
Noncontrolling interests | 171.95%446M | -63.01%658M | 13.30%230M | -50.91%162M | -86.14%102M | -67.84%164M | 3.13%1.78B | -56.72%203M | -43.49%330M | 103.88%736M |
Net income attributable to the company | -40.87%8.03B | 17.16%48.07B | 9.97%12.91B | -25.46%9.29B | 37.04%12.28B | 72.84%13.58B | 59.04%41.03B | 47.20%11.74B | 113.71%12.47B | 56.36%8.96B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -40.87%8.03B | 17.16%48.07B | 9.97%12.91B | -25.46%9.29B | 37.04%12.28B | 72.84%13.58B | 59.04%41.03B | 47.20%11.74B | 113.71%12.47B | 56.36%8.96B |
Gross dividend payment | ||||||||||
Basic earnings per share | -40.30%44.6267 | 19.51%264.88 | 11.10%71.4367 | -24.02%51.1233 | 40.92%67.57 | 77.57%74.75 | 60.26%221.63 | 50.46%64.3 | 115.21%67.2833 | 56.09%47.95 |
Diluted earnings per share | -40.30%44.6267 | 19.51%264.88 | 11.10%71.4367 | -24.02%51.123 | 40.92%67.57 | 77.57%74.75 | 60.26%221.63 | 50.47%64.3 | 115.21%67.2833 | 56.09%47.95 |
Dividend per share | 0 | 42.86%66.6667 | 60.00%40 | 0 | 23.08%26.6667 | 0 | 40.00%46.6667 | 25.00%25 | 0 | 62.50%21.6667 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |